The Bobby Darin musical "Just in Time" has achieved what few Broadway shows accomplish: profitability. Producers confirm the production has recouped its $12.5 million capitalization costs, making it the first new musical from the 2024-2025 season to turn a profit for investors. The biomusical chronicles the life of the 1960s pop star through hits like "Mack the Knife" and "Beyond the Sea."

During Jonathan Groff's final week in late March, the show grossed over $2 million with average ticket prices reaching $362—far exceeding Broadway's weekly average of $131. The production operates at the intimate 690-seat Circle in the Square Theater, which keeps running costs lower than typical Broadway houses. This fiscal discipline, combined with strong star power, proved essential to reaching the profit milestone.

The show's success defied industry expectations. Critics were skeptical about Darin's name recognition since his 1973 death, and the production earned no Tony Awards despite six nominations. Producer Tom Kirdahy acknowledged that "the industry missed the boat on this one, but the audience didn't." The musical joins a select post-pandemic group of profitable new Broadway musicals including "MJ" and "Six."

With plans for a North American tour launching next summer, "Just in Time" demonstrates that smaller-scale productions with disciplined budgets can still thrive on Broadway. The show continues running indefinitely, proving that profitability remains achievable even in an increasingly risky theater market.